CordenPharma to invest $10.9 million in oral solid drug manufacturing

Article

CDMO’s financial commitment will feature construction of a new GMP clinical trial development facility

CordenPharma, a full-service contract development manufacturing organization (CDMO) of active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, is investing $10.9 million into the design and installment of a new good manufacturing practice (GMP) clinical trial development (CTD) facility for the manufacturing of oral solid dosage drug products at its Plankstadt plant, located near Heidelberg, Germany.

According to the company, the installment of the new CTD center at CordenPharma Plankstadt comes in response to customers’ demands, along with the recognition of gaps in scale, formulation development technologies for insoluble APIs and manufacturing of capsule products.

The Plankstadt plant specializes in the safe handling of highly potent APIs and drug products, providing services for pharmaceutical development, such as manufacturing (from early-stage development to full commercial scale), packaging, and pharma logistics.

Among its features, the facility will be equipped with various oral solid dosage manufacturing needs, including blending, granulation (high shear, fluid bed, roller compaction), compression and coating. Investments in high potency filling equipment (powders, pellets, mini-tablets) into capsules, hot melt extrusion (HME) and the ability to operate with organic solvents are also being added. Work on the project is already underway, and there is a targeted completion date of Q3 2022.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.